Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer - PubMed (original) (raw)
Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer
Ruey-Kuen Hsieh et al. Chest. 2005 Jul.
Abstract
Study objectives: The prevalence of epidermal growth factor receptor (EGFR) mutations in gefitinib-naive lung cancer patients is higher in adenocarcinomas, in women, and in Japanese. To further investigate the prevalence of EGFR mutations in relation to ethnic and geographic factors, we evaluated EGFR mutations in a series of Taiwanese patients with primary lung adenocarcinomas who had never been treated with gefitinib.
Design and methods: We retrospectively studied 35 primary lung adenocarcinoma samples for mutations in the tyrosine kinase domain of EGFR; exons 18, 19, and 21 were analyzed by nested polymerase chain reaction and automated sequencing. Clinicopathologic information was obtained from patient records and pathology reports. Correlation between EGFR mutations and patient characteristics, including sex, smoking history, and pathologic subtypes, were evaluated by using the chi(2) test and logistic regression analysis.
Results: Heterozygous EGFR mutations were detected in 17 of 35 patients (48%). Missense mutations in exon 21 (13 of 17 patients, 76%) were the most frequent mutations detected. EGFR mutations were more frequent in women (13 of 18 patients [72%]) than in men (4 of 17 patients [23%]; p = 0.004), more frequent in nonsmokers (14 of 21 patients [66%]) than in current smokers (3 of 14 patients [21%]; p = 0.009), and when any degree of bronchioloalveolar carcinoma (BAC) was present (14 of 21 patients [66%]) compared with pure adenocarcinoma (3 of 14 patients [21%]; p = 0.009). Logistic regression analysis demonstrated that female gender (odds ratio [OR], 10.913; 95% confidence interval [CI], 1.778 to 66.97; p = 0.01) and BAC, including adenocarcinomas with any bronchioloalveolar features (OR, 9.708; 95% CI, 1.464 to 64.393; p = 0.019), were significantly associated with EGFR mutations.
Conclusions: In our series, female sex and bronchioloalveolar pathologic subtype predicted the presence of EGFR mutations in lung adenocarcinomas, and the high frequency of EGFR mutations supports the hypothesis that genetic backgrounds and/or environmental factors may affect the pathogenesis of certain lung cancers.
Similar articles
- High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee CT, Lee JS, Chung JH. Sun PL, et al. J Thorac Oncol. 2012 Feb;7(2):323-30. doi: 10.1097/JTO.0b013e3182381515. J Thorac Oncol. 2012. PMID: 22237264 - A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma.
Haneda H, Sasaki H, Lindeman N, Kawano O, Endo K, Suzuki E, Shimizu S, Yukiue H, Kobayashi Y, Yano M, Fujii Y. Haneda H, et al. Jpn J Clin Oncol. 2006 Feb;36(2):69-75. doi: 10.1093/jjco/hyi228. Epub 2006 Jan 31. Jpn J Clin Oncol. 2006. PMID: 16449241 - Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Kris MG, Giaccone G, Davies A, Fukuoka M, Garfield DH, Jassem J, Quoix EA, Sandler AB, Scagliotti GV, Van Meerbeeck JP, West H. Kris MG, et al. J Thorac Oncol. 2006 Nov;1(9 Suppl):S32-6. J Thorac Oncol. 2006. PMID: 17409999 - Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?
Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Inamura K, et al. Arch Pathol Lab Med. 2010 Jan;134(1):66-72. doi: 10.5858/2008-0586-RAR1.1. Arch Pathol Lab Med. 2010. PMID: 20073607 Review.
Cited by
- Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR. Rodig SJ, et al. Clin Cancer Res. 2009 Aug 15;15(16):5216-23. doi: 10.1158/1078-0432.CCR-09-0802. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671850 Free PMC article. - Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.
Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, Riely GJ, Rusch VW, Adusumilli PS, Travis WD. Kadota K, et al. Am J Surg Pathol. 2014 Apr;38(4):448-60. doi: 10.1097/PAS.0000000000000134. Am J Surg Pathol. 2014. PMID: 24472852 Free PMC article. - Molecular epidemiology of female lung cancer.
Yim SH, Chung YJ. Yim SH, et al. Cancers (Basel). 2011 Apr 1;3(2):1861-76. doi: 10.3390/cancers3021861. Cancers (Basel). 2011. PMID: 24212786 Free PMC article. - Expression of EGFR Is Closely Related to Reduced 3-Year Survival Rate in Chinese Female NSCLC.
Sun G, Liu B, He J, Zhao X, Li B. Sun G, et al. Med Sci Monit. 2015 Jul 31;21:2225-31. doi: 10.12659/MSM.894786. Med Sci Monit. 2015. PMID: 26230859 Free PMC article. - Evaluation of liquid based cytology in detection of EGFR mutation in NSCLC by large samples.
Dong Z, Cao Z, Wu W, Zhang L, Hou L, Zhang W, Wu C. Dong Z, et al. J Thorac Dis. 2020 Sep;12(9):4941-4949. doi: 10.21037/jtd-20-2750. J Thorac Dis. 2020. PMID: 33145068 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous